Allergan Lobs More Criticism Amid $53B Valeant Buyout Push
Allergan Inc. on Monday tore into Valeant Pharmaceuticals International Inc.'s promise to increase transparency and deliver growth, the company's latest effort to slow down a $53 billion takeover campaign launched by...To view the full article, register now.
Already a subscriber? Click here to view full article